Gu L, Okada Y, Clinton S K, Gerard C, Sukhova G K, Libby P, Rollins B J
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Mol Cell. 1998 Aug;2(2):275-81. doi: 10.1016/s1097-2765(00)80139-2.
Recruitment of blood monocytes into the arterial subendothelium is one of the earliest steps in atherogenesis. Monocyte chemoattractant protein-1 (MCP-1), a CC chemokine, is one likely signal involved in this process. To test MCP-1's role in atherogenesis, low density lipoprotein (LDL) receptor-deficient mice were made genetically deficient for MCP-1 and fed a high cholesterol diet. Despite having the same amount of total and fractionated serum cholesterol as LDL receptor-deficient mice with wild-type MCP-1 alleles, LDL receptor/MCP-1-deficient mice had 83% less lipid deposition throughout their aortas. Consistent with MCP-1 's monocyte chemoattractant properties, compound-deficient mice also had fewer macrophages in their aortic walls. Thus, MCP-1 plays a unique and crucial role in the initiation of atherosclerosis and may provide a new therapeutic target in this disorder.
血液单核细胞募集到动脉内皮下是动脉粥样硬化形成的最早步骤之一。单核细胞趋化蛋白-1(MCP-1),一种CC趋化因子,是参与这一过程的一个可能信号。为了测试MCP-1在动脉粥样硬化形成中的作用,使低密度脂蛋白(LDL)受体缺陷小鼠在基因上缺乏MCP-1,并给予高胆固醇饮食。尽管LDL受体/MCP-1缺陷小鼠的总血清胆固醇和分级血清胆固醇水平与具有野生型MCP-1等位基因的LDL受体缺陷小鼠相同,但它们主动脉中的脂质沉积减少了83%。与MCP-1的单核细胞趋化特性一致,复合缺陷小鼠主动脉壁中的巨噬细胞也较少。因此,MCP-1在动脉粥样硬化的起始过程中发挥着独特而关键的作用,可能为这种疾病提供一个新的治疗靶点。